Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

RARITAN, N.J., Dec. 29, 2021. The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials